Pfizer has announced a global strategic collaboration with France-based Cellectis for development of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets.
Cellectis claims that its CAR-T technology provides an allogeneic approach to developing CAR-T therapies that is distinct from other autologous approaches.
Go deeper with GlobalData
Under the terms, Pfizer will have exclusive rights to develop and commercialise CAR-T therapies in the field of oncology, directed at a total of 15 targets selected by the company.
Pfizer and Cellectis will work together on preclinical research, with Pfizer responsible for development and potential commercialisation of any CAR-T therapies for company-selected targets.
In addition, the agreement provides for a total of 12 targets selected by Cellectis. Both companies will work together on preclinical research on four Cellectis-selected targets, while Cellectis will work independently on eight additional targets.
Cellectis will be responsible for clinical development and commercialisation of CAR-T therapeutics for company-selected targets.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataUnder the deal, Pfizer will pay an upfront payment of $80m to Cellectis, as well as funding for research and development costs associated with Pfizer-selected targets and the four Cellectis-selected targets within the collaboration.
Cellectis will also be eligible to get development, regulatory and commercial milestone payments of up to $185m per Pfizer product, plus tiered royalties on any eventual sales.
In addition, Pfizer will also buy a stake of 10% in Cellectis through newly issued shares at €9.25 per share, pending Cellectis shareholder approval. Pfizer has the option to terminate the collaboration agreement if the sale of equity is not approved by the Cellectis shareholders.
Pfizer R&D president Dr Mikael Dolsten said: "Combining the innovation and scientific expertise of Cellectis with Pfizer’s deep oncology and immunology experience creates a world-class partnership designed to deliver a new generation of CAR-T immunotherapies for cancer patients with urgent medical needs."
